Agree, I think 2024 we should see revenue looking good in the financials.
Markets are forward looking so we should see some SP movement earlier than revenue appears in the Financials.
BRN Discussion Ongoing
- Thread starter TechGirl
- Start date
Markets are forward looking so we should see some SP movement earlier than revenue appears in the Financials.
Dhm
Regular
Just back to the NDA thing, when a company is shown Akida and registers a high degree of excitement yet secrecy about the ‘principle’ of the AI, and decides to do further testing for say a further 3-6 months without any contract signed, yet for whatever reason subsequently walks away, would this company be part of the 100 NDA’s? I’m guessing that we as shareholders aren’t privy to these situations.
Another part of my questioning is, do NDAs come and go and fall away quite regularly in the world of secrecy?
Another part of my questioning is, do NDAs come and go and fall away quite regularly in the world of secrecy?
Food4 thought
Regular
That why I have had a five year plan,
I am about 1/2 way through it and will consider any actions at the end of the 5 years, hold or sell
Food4 thought
Regular
Well given the fact that this forum is about BrainChip let’s just talk about that.
When I invested in Brn originally I knew it would be a long time to get things happening, to have produced and have product on the shelves.
We are not selling fast food
It’s no McDonald’s
Look at any tech firm go and do research on how long their journey have taken them to get traction in the market place.
But with world events that have happened over the last 3 years, that has slowed the wheels down considerably.
So I don’t think we will see much happen before mid 2024 but then it should go ballistic,if everything falls our way.
I see June this year as the start of the slow gathering of open information and increased sales thanks to Mercedes
Then others will start to revel them selves Dell will be coming out soon
Have faith
Hold tight
God speed
Rise from the ashes
Regular
Yeah but my question was if something drastically changed let's just say the future chips totally failed which would turn this stock worthless. You'd still hold for the 5 year plan? And obviously I'm not saying that will happen but I've had the x amount of years plan before and failed miserably by ignoring major stuff ups. Never again will I ignore and blindly stick to a plan
Last edited:
This news article only a few hours old is an excellent read, check it out....pity they didn't actually interview a real
neuroscientist who's actually in the real world, as in, the commercial sense, not from academia, never-the-less it's
still a nice article.
www.9news.com.au
Texta
neuroscientist who's actually in the real world, as in, the commercial sense, not from academia, never-the-less it's
still a nice article.
Will AI ever reach human-level intelligence? Five experts weigh in
There's no doubt AI systems appear to be "intelligent" to some extent. But could they ever be as intelligen...
Texta
D
Deleted member 118
Guest
Well if it does as I’ve a 7 year plan on retiring when Im 60 I’ll guess i will be living in a
TechGirl
Founding Member
Interesting know labs have proof of principle with edge impulse
SEATTLE – April 21, 2023 –Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of a proof-of-principle study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” conducted in collaboration with Mayo Clinic. Know Labs will present the results of the study at the American Physiological Society (APS) Summit, which is being held on April 20-23 in Long Beach, California. The study demonstrates the accuracy of Know Labs’ proprietary Bio-RFID™ sensor in quantifying different analytes in vitro, proving a 100% accuracy rate in these tests. The full study is currently undergoing the peer-review publishing process.
Know Labs’ technology platform, Bio-RFID, uses electromagnetic energy in the form of radio waves to non-invasively capture molecular signatures, which can be converted into physiologically meaningful information and insights. While the technology is proven to accurately measure several analytes inside and outside the body, the first application of this technology is aimed at non-invasive glucose monitoring.
“Proof-of-principle studies are critical in demonstrating Bio-RFID’s accuracy for non-invasive methods of medical diagnostics. This was an essential step toward achieving our goal of delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market,” said Ron Erickson, CEO and Chairman at Know Labs. “To put this into real-world context: imagine being able to continuously and accurately measure different aspects of your health on a molecular level using a pocket-sized (or smaller) sensor instead of a finger prick or a CGM probe.”
Conducted at Mayo Clinic in Rochester, MN in March of 2021, the study included five experiments designed to demonstrate the ability of the Bio-RFID sensor to non-invasively quantify concentrations of solutions using a randomized double-blind trial design, as proxies for biochemical solutions. Solutions including water in isopropyl alcohol, sodium chloride in water, and commercial bleach in water were tested. Data were collected using the Bio-RFID sensor, which generates radio frequency signals and measures received power through an antenna array. The sensor sweeps across the 1500 Megahertz (MHz) - 3000 MHz range at 0.2 MHz intervals, collecting values at 7501 frequencies.
“Market pressures like rising healthcare costs and the rapid increase in remote patient monitoring and care delivery are driving the need for affordable, accurate and non-invasive continuous measures of blood analytes,” said James “Andy” Anderson, M.D., Chief Medical Officer at Know Labs. “What we are describing here is truly ground-breaking. This novel application of the Bio-RFID technology to accurately detect and quantify specific molecules in liquid provides strong support for non-invasive monitoring of physiologically and medically relevant analytes in the human body.”
For each of the five experiments, 100% of solutions in the test data were correctly identified. The Bio-RFID technology was able to detect concentrations as low as 2000 parts per million (ppm) – which is equivalent to accurately measuring the difference of 0.7ml of water dropped into a 12oz can of soda – with evidence suggesting the ability to detect much smaller concentration differences. These in vitro findings provide proof-of-principle, strongly supporting the application of the technology for further non-invasive, physiologic and medical monitoring.
This proof-of-principle study is part of a series of studies that Know Labs is conducting as the company prioritizes external validation of its Bio-RFID technology in detecting and measuring glucose and other analytes in the body non-invasively at high levels of accuracy.
The study abstract and APS Summit Poster can be viewed at www.knowlabs.co. The full manuscript will be published following peer review.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
Know Labs Demonstrates Accuracy of Non-Invasive, Bio-RFID Technology with Proof-of-Principle Study
SEATTLE – April 21, 2023 –Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of a proof-of-principle study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” conducted in collaboration with Mayo Clinic. Know Labs will present the results of the study at the American Physiological Society (APS) Summit, which is being held on April 20-23 in Long Beach, California. The study demonstrates the accuracy of Know Labs’ proprietary Bio-RFID™ sensor in quantifying different analytes in vitro, proving a 100% accuracy rate in these tests. The full study is currently undergoing the peer-review publishing process.
Know Labs’ technology platform, Bio-RFID, uses electromagnetic energy in the form of radio waves to non-invasively capture molecular signatures, which can be converted into physiologically meaningful information and insights. While the technology is proven to accurately measure several analytes inside and outside the body, the first application of this technology is aimed at non-invasive glucose monitoring.
“Proof-of-principle studies are critical in demonstrating Bio-RFID’s accuracy for non-invasive methods of medical diagnostics. This was an essential step toward achieving our goal of delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market,” said Ron Erickson, CEO and Chairman at Know Labs. “To put this into real-world context: imagine being able to continuously and accurately measure different aspects of your health on a molecular level using a pocket-sized (or smaller) sensor instead of a finger prick or a CGM probe.”
Conducted at Mayo Clinic in Rochester, MN in March of 2021, the study included five experiments designed to demonstrate the ability of the Bio-RFID sensor to non-invasively quantify concentrations of solutions using a randomized double-blind trial design, as proxies for biochemical solutions. Solutions including water in isopropyl alcohol, sodium chloride in water, and commercial bleach in water were tested. Data were collected using the Bio-RFID sensor, which generates radio frequency signals and measures received power through an antenna array. The sensor sweeps across the 1500 Megahertz (MHz) - 3000 MHz range at 0.2 MHz intervals, collecting values at 7501 frequencies.
“Market pressures like rising healthcare costs and the rapid increase in remote patient monitoring and care delivery are driving the need for affordable, accurate and non-invasive continuous measures of blood analytes,” said James “Andy” Anderson, M.D., Chief Medical Officer at Know Labs. “What we are describing here is truly ground-breaking. This novel application of the Bio-RFID technology to accurately detect and quantify specific molecules in liquid provides strong support for non-invasive monitoring of physiologically and medically relevant analytes in the human body.”
For each of the five experiments, 100% of solutions in the test data were correctly identified. The Bio-RFID technology was able to detect concentrations as low as 2000 parts per million (ppm) – which is equivalent to accurately measuring the difference of 0.7ml of water dropped into a 12oz can of soda – with evidence suggesting the ability to detect much smaller concentration differences. These in vitro findings provide proof-of-principle, strongly supporting the application of the technology for further non-invasive, physiologic and medical monitoring.
This proof-of-principle study is part of a series of studies that Know Labs is conducting as the company prioritizes external validation of its Bio-RFID technology in detecting and measuring glucose and other analytes in the body non-invasively at high levels of accuracy.
The study abstract and APS Summit Poster can be viewed at www.knowlabs.co. The full manuscript will be published following peer review.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
D
Deleted member 1269
Guest
@dippY22, I want BrainChip to be as successful as every other shareholder, we all want the same thing.
But just a cut and paste from last years AGM -
Im my opinion, when the CEO is taking about but being judged on results specifically around commercialisation, this means financial results to me.
Ella and I are 99.9° % sure that Untether have their own in-house design:
US2021091794A1 COMPUTATIONAL MEMORY WITH ZERO DISABLE AND ERROR DETECTION
A processing element includes an input zero detector to detect whether the input from the neighbor processing element contains a zero. When the input from the neighbor processing element contains the zero, a zero disable circuit controls the input from the neighbor processing element and respective data of the memory to both appear as unchanged to the arithmetic logic unit for the operation. A controller of an array of processing elements adds a row of error-checking values to a matrix of coefficients, each error-checking value of the row of error-checking values being a negative sum of a respective column of the matrix of coefficients. The controller controls a processing element to perform an operation with the matrix of coefficients and an input vector to accumulate a result vector. Owing to the error-checking values, when a sum of elements of the result vector is non-zero, an error is detected.
Technology — Untether AI
https://www.untether.ai/technology
runAI200™ Represents a new breed of computing
At Untether AI, we re-wrote the rules for compute architectures. Designed from the ground up for AI inference workloads, the runAI200® architecture provides best-in-class performance for running neural networks; CNNs, RNNs, TCNs, Attention, Transformer, Unets, and DLRM.
At the heart of the unique at-memory compute architecture is a memory bank: 385KBs of SRAM with a 2D array of 512 processing elements. With 511 banks per chip, each device offers 200MB of memory, enough to run many networks in a single chip. And with the multi-chip partitioning capability of the imAIgine® Software Development Kit, larger networks can be split apart to run on multiple devices, or even across multiple tsunAImi® accelerator cards.
Deadpool
Did someone say KFC
Bravo
If ARM was an arm, BRN would be its biceps💪!
Hi @caroorac,
There are many research papers delving into entrepreneurial approaches in commercialising new technologies. Key findings are that relationships with partners and other supporting companies/organisations need to be formed earlier than previous literature suggested hence the early focus on communication and partnership is highlighted as being a critical factor for rapid commercialisation success.
This usually involves an ecosystem model which brings together compatible technology companies, experienced business leaders, researchers, etc.
This is an extract from @SERA2g post #54,500, which might help show the results of this commercialisation process in BrainChip's case.
SiFive, nViso, ARM, Prophesee, Edge Impulse, AI Labs, IFS, Blue Ridge, Teksun, emotion3D, three Unis, ... and none of these made it into the MF article?
D
Deleted member 1269
Guest
For me personally, there is nothing Sean can "say" to give me confidence. I'm afraid his words are hollow for me. I need cold hard evidence. Not EAPs, not potential clients under NDAs, not partnerships, but deals that are resulting in actual revenue. It's time for action not words in my opinion.
Bravo
If ARM was an arm, BRN would be its biceps💪!
Did you read my reply to your first post @caroorac? I'm interested in how you would describe all of partnerships and ecosystem building that occurred between this AGM and last. If you don't equate that activity to a result, then what else would you describe it as being?
Last edited:
Bravo
If ARM was an arm, BRN would be its biceps💪!
You don't have to take my word for it. Here are some other sources of information, if you'd like to read up on it.
Why Ecosystem Readiness Is Key For The Success Of New Products
An ecosystem is like a domino structure: You must make sure that all the entities in the ecosystem support your business initiative in order to succeed.
www.forbes.com
Successful Ecosystem Collaboration for a Purpose-driven Growth
Read how a successful ecosystem collaboration can help businesses achieve purpose-driven growth and prioritize ESG culture for long-term business viability.
D
Deleted member 118
Guest
Similar threads
